AURINIA PHARMACEUTICALS INC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2012-01-01
- Employees
- -
- Market Cap
- -
Long-Term Voclosporin Treatment in Adolescent Subjects With Lupus Nephritis
Phase 3
Not yet recruiting
- Conditions
- Adolescent Lupus Nephritis
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Aurinia Pharmaceuticals Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05962788
A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Aurinia Pharmaceuticals Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT05337124
- Locations
- 🇺🇸
Site 00-05, S. Gate, California, United States
Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Aurinia Pharmaceuticals Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05306379
- Locations
- 🇺🇸
Labcorp Clinical Research Unit, Dallas, Texas, United States
Voclosporin in Adolescents With Lupus Nephritis
Phase 3
Recruiting
- Conditions
- Adolescent Lupus Nephritis
- Interventions
- Drug: Placebo Oral CapsuleDrug: Voclosporin
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Aurinia Pharmaceuticals Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05288855
- Locations
- 🇺🇸
UNC-Chapel Hill, Chapel Hill, North Carolina, United States
Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome
Phase 2
Completed
- Conditions
- Keratoconjunctivitis SiccaDry Eye Syndrome
- Interventions
- Drug: 0.10% VOSDrug: 0.05% Voclosporin Ophthalmic Solution (VOS)Drug: 0.20% VOSDrug: Vehicle Ophthalmic Solution
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Aurinia Pharmaceuticals Inc.
- Target Recruit Count
- 508
- Registration Number
- NCT04147650
- Locations
- 🇺🇸
Aurinia Investigative Center, Nashville, Tennessee, United States
Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Aurinia Pharmaceuticals Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT03598036
- Locations
- 🇩🇴
FSGS Investigative Center, Santo Domingo, Dominican Republic
🇺🇸FSGS Investigative Site, Salt Lake City, Utah, United States
🇩🇴FSGS Investigative Centre, Santiago De Los Caballeros, Dominican Republic
Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Aurinia Pharmaceuticals Inc.
- Target Recruit Count
- 216
- Registration Number
- NCT03597464
- Locations
- 🇺🇸
AURORA Investigative Center, Oklahoma City, Oklahoma, United States
Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2021-07-08
- Lead Sponsor
- Aurinia Pharmaceuticals Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT03597139
- Locations
- 🇺🇸
Aurinia Investigative Center, Memphis, Tennessee, United States
Aurinia Renal Response in Active Lupus With Voclosporin
- First Posted Date
- 2017-01-16
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Aurinia Pharmaceuticals Inc.
- Target Recruit Count
- 358
- Registration Number
- NCT03021499
- Locations
- 🇻🇳
AURORA Investigative Center, Ho Chi Minh City, Vietnam
🇧🇾AURORA Investigative Cener, Minsk, Belarus
🇺🇸AURORA, Richmond, Virginia, United States
Voclosporin in Healthy Japanese Volunteers
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- Aurinia Pharmaceuticals Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02949999
- Locations
- 🇵🇭
MAD VCS Site, Dasmarinas City, Cavite, Philippines
© Copyright 2025. All Rights Reserved by MedPath